SCHEMBL20557488

SCHEMBL20557488

CC(C)(C)OC(=O)N1CC(=O)c2cn(C(c3ccccc3)(c3ccccc3)c3ccccc3)nc2C1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.37
MAPK1 P28482 1/20 0.37
PARP1 P09874 1/20 0.37
TNKS2 Q9H2K2 1/20 0.37
PARP2 Q9UGN5 1/20 0.37
RORC P51449 2/20 0.36
TACR1 P25103 1/20 0.36
CKS1B P61024 1/20 0.35
SKP1 P63208 1/20 0.35
SKP2 Q13309 1/20 0.35
GRM5 P41594 1/20 0.35
GRM1 Q13255 1/20 0.35
NAMPT P43490 3/20 0.35
USP30 Q70CQ3 2/20 0.35
PDK4 Q16654 1/20 0.35
KDM4E B2RXH2 1/20 0.34
PKM P14618 1/20 0.34
SCD5 Q86SK9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4134292 0.78 RORC (0.39) GPR119MAPK1RORCNAMPTUSP30
SCHEMBL29813840 0.72 MAPK1 (0.54) GPR119MAPK1NAMPTPDK4
SCHEMBL17369314 0.72 MAPK1 (0.54) GPR119MAPK1NAMPTPDK4
SCHEMBL21638923 0.71 KMT2A (0.47) MAPK1PARP1TNKS2PARP2CKS1B
SCHEMBL4688868 0.70 RORC (0.40) GPR119RORCNAMPTUSP30KDM4E
SCHEMBL22030526 0.70 PARP1 (0.40) GPR119MAPK1PARP1TNKS2PARP2
SCHEMBL3601682 0.69 ELANE (0.44) GRM5KDM4E
SCHEMBL31080015 0.68 USP2 (0.50) GPR119MAPK1KDM4E
SCHEMBL4138894 0.68 POLB (0.49) GPR119
SCHEMBL22403012 0.68 PDK2 (0.50) MAPK1NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110709081-B Compounds and methods for treating bacterial infections 恩塔西斯治疗公司 2023-09-22 CN disclosed
EP-3630111-B1 COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS ENTASIS THERAPEUTICS INC (US) 2021-11-24 EP disclosed
US-11046694-B2 Compounds and methods for treating bacterial infections ENTASIS THERAPEUTICS, INC. (US) 2021-06-29 US disclosed
US-20200165251-A1 COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS ENTASIS THERAPEUTICS, INC. 2020-05-28 US disclosed
EP-3630111-A1 COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS Entasis Therapeutics, Inc. (US) 2020-04-08 EP disclosed
CN-110709081-A Compounds and methods for treating bacterial infections 恩塔西斯治疗公司 2020-01-17 CN disclosed
WO-2018208769-A1 COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS ENTASIS THERAPEUTICS, INC. (US) 2018-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11046694-B2 Compounds and methods for treating bacterial infections MRPL21, CFTR, C5 GPR119 1377/4885MAPK1 946/4885PARP1 2545/4885
US-20200165251-A1 COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS MRPL21, CFTR, C5 GPR119 1377/4885MAPK1 946/4885PARP1 2545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.